IrisMessi
Lv2
190 积分
2022-02-24 加入
-
637 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Onset of action and maintenance of response in the phase 3 POETYK PSO-3 trial
10小时前
已完结
-
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
10天前
已完结
-
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
11天前
已完结
-
CGRP as the target of new migraine therapies — successful translation from bench to clinic
12天前
已完结
-
Lifestyle factors and migraine
14天前
已完结
-
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
2个月前
已完结
-
Mechanism underlying the effect of MnO2 nanosheets for A549 cell chemodynamic therapy
2个月前
已完结
-
A Forward Vision for Chemodynamic Therapy: Issues and Opportunities
2个月前
已完结
-
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
2个月前
已完结
-
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
5个月前
已完结